louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00524212: How to Improve Diagnosis in Infective Endocarditis
Official title: Ph. D Student, Jane Byriel Knudsen, Aarhus University
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endocarditis, Bacterial
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2007-09-03
Enrollment: 761
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The cohort was selected from all the patients admitted to the tertiary hospital (the initial diagnosis was infective endocarditis)

Brief summary: The purpose is to exam prospective if simple clinical information in combination with a normal s-procalcitonin are sufficient for exclusion of infective endocarditis (IE).

Detailed description: Despite progress in surgical and medical treatment, infective endocarditis is still associated with high morbidity and mortality.

The variable clinical presentation of IE makes the diagnosis a clinical challenge.

Procalcitonin is a precursor from the hormone calcitonin and also a marker of systemic bacterial infections.

The purpose of this study is:

* to investigate the diagnostic value of serum procalcitonin (PCT), C-reactive protein (CRP) and sedimentation rate (SR) when IE is suspected.
* to investigate if a retrospectively generated clinical model suitable for exclusion of IE can be confirmed prospectively.

Eligibility criteria: Inclusion Criteria:

* Patients \> or = 18 year with suspected or verified Infective Endocarditis
* By word of mouth or in writing consent

Exclusion Criteria:

* Incapacity

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Department of Cardiology, Aarhus University Hospital
Study officials:
affiliation: Aarhus University Hospital, Skejby, Department of Cardiology, 8200 Aarhus N, Denmark
name: Jane B Knudsen, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06024512: DeepView Snapshot Handheld (DV-H) Comparison Study
Official title: DeepView Snapshot Handheld (DV-H) Comparison Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Burns
Lead sponsor: SpectralMD
Sponsor class: INDUSTRY
First posted: 2023-09-06
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: The goal of this prospective study is to evaluate Study Burns from up to 22 Subjects. Adult will be defined as Subjects 18 years of age or older.

Brief summary: his study is being done to collect pictures of burns using an investigational device called the Spectral MD Deep View Snapshot Handheld (DV-H), similar to a camera. The data collected will be used to assess the performance of the DV-H device, and to determine the device's ability to differentiate healing versus non-healing burn tissue. This device, if approved, is expected to give caregivers a better understanding of what parts of burn wounds will likely not heal on their own and as a tool used by the military in the field. This current study involves the collection of images over the course of your clinical treatment and follow-up according to your routine standard of care. The device will not be used to diagnose or prescribe treatment for your burn


Eligibility criteria: Inclusion Criteria:

.Age \>18 years and able to give informed consent or have a Legally Authorized Representative (LAR) able to do so;

* Life expectancy \> 6 months;
* Thermal burn mechanism (flame, scald, or contact);
* The Study Burn(s) occurred less than 72 hours prior to the time of first imaging;
* Minimum burn wound size for patients is 0.5% TBSA per region
* Have 2 - 4 regions of their clinical burn(s) that meet the criteria for a Study Burn; and

Exclusion Criteria:

* Patients will be excluded if any of the following conditions apply:

  * Burn pattern distribution isolated to head, face, neck, hands, feet, genitalia, and/or joints;
  * Subject has burns involving \> 50% total body surface area (TBSA);
  * Sepsis at the time of enrollment determined by diagnosis made by Principal Investigator or Sub-Investigator;
  * Immunosuppression/radiation/chemotherapy \< 3 months prior to enrollment;
  * Concurrent use of investigational products with a known effect on the burn sites; and/or
  * Any condition that in the opinion of the Investigator may prevent compliance with the study requirements or compromise subject safety.

Primary outcomes:
measure: DeepView Snapshot Handheld (DV-SSH) Comparison Study Protocol
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: New Orleans
country: United States
facility: LSU Health New Orleans University Medical Center New Orleans
state: Louisiana
Study officials:
References:
Clinical trial NCT00746512: A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)
Official title: A Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Access the Effects of Oral Prednisone on Clinical Efficacy and the Power Doppler Ultrasound Signal of Synovium in Patients With Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Rheumatoid Arthritis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2008-09-04
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will compare the effects of prednisone vs placebo on synovial blood flow and overall DAS (disease activity score) in patients with rheumatoid arthritis.


Eligibility criteria: Inclusion Criteria:

* Patient is willing to limit alcohol intake to 3 or less beverages per day
* Patient agrees to use only acetaminophen/paracetamol for breakthrough pain

Exclusion Criteria:

* Patient has other inflammatory arthritis (e.g. lupus). Patient has had major surgery or donated or lost 1 unit of blood in the last 4 weeks
* Patient has a history of drug or alcohol abuse in the last 2 years
* Patient has had a vaccine (with a live or attenuated virus) in the last two weeks

Primary outcomes:
measure: Synovial Blood Flow
timeFrame: Baseline and Day 14
Secondary outcomes:
measure: Disease Activity Score 28 (DAS28) (C-reactive Protein [CRP])
timeFrame: Baseline and Day 14
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Seymour MW, Kelly S, Beals CR, Malice MP, Bolognese JA, Dardzinski BJ, Cheng AS, Cummings CE, Smugar SS, McClinton C, Fox A, Dooley WM, Pitzalis C, Taylor PC. Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study. Arthritis Res Ther. 2012 Sep 12;14(5):R198. doi: 10.1186/ar4034.
Clinical trial NCT04065412: Modified Laryngeal Handshake Technique
Official title: Modified Laryngeal Handshake Technique for Locating the Cricothyroid Membrane
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Airway Complication of Anesthesia
Lead sponsor: SMG-SNU Boramae Medical Center
Sponsor class: OTHER
First posted: 2019-08-22
Enrollment: 200
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: In this study, we compare the conventional laryngeal handshake technique and modified laryngeal handshake technique for locating the cricothyroid membrane in terms of accuracy and speed. The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.

The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.


Eligibility criteria: Inclusion Criteria:

* Patients who would be scheduled elective surgery under general anesthesia

Exclusion Criteria:

* Diseases or anatomical abnormalities in the neck or larynx
* History of neck surgery

Primary outcomes:
measure: The accuracy to localize the cricothyoid membrane
timeFrame: 1 minute after identifying the cricothyroid membrane using the conventional or modified laryngeal handshake technique
Secondary outcomes:
measure: The accuracy to localize the midline of the neck
timeFrame: through the identification of cricothyroid membrane, an average of 5 minutes
measure: The vertical and horizontal distances between the actual and perceived cricothyroid membrane
timeFrame: through the identification of cricothyroid membrane, an average of 5 minutes
measure: Time to localize the cricothyroid membrane
timeFrame: through the identification of cricothyroid membrane, an average of 5 minutes
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: SMG-SNU Boramae Medical Center
Study officials:
affiliation: SMG-SNU Boramae Medical Center
name: Jin-Young Hwang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chang JE, Kim H, Won D, Lee JM, Kim TK, Min SW, Hwang JY. Comparison of the Conventional Downward and Modified Upward Laryngeal Handshake Techniques to Identify the Cricothyroid Membrane: A Randomized, Comparative Study. Anesth Analg. 2021 Nov 1;133(5):1288-1295. doi: 10.1213/ANE.0000000000005744.
Clinical trial NCT01310712: Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study
Official title: Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hyperhidrosis
Keywords: hyperhidrosis
oxybutynin
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2011-03-08
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Video-assisted thoracic sympathectomy (VATS) provides excellent resolution of palmar and axillary hyperhidrosis but is associated with compensatory hyperhidrosis. Low doses of Oxybutynin can be used to treat palmar hyperhidrosis with fewer side effects.

Detailed description: Introduction: Video-assisted thoracic sympathectomy (VATS) provides excellent resolution of palmar and axillary hyperhidrosis but is associated with compensatory hyperhidrosis. Low doses of Oxybutynin can be used to treat palmar hyperhidrosis with fewer side effects.

Purpose: The objective of this study is to evaluate the effectiveness and patient satisfaction with the use of oxybutynin at low doses comparing to placebo for treating palmar hyperhidrosis.

Methods: This is a prospective, randomized and controlled study. From December 2010 to february 2011, 50 consecutive patients with palmar hyperhidrosis were treated with oxybutynin or placebo. Data were collected from 50 patients, and 5 (10,0%) patients were lost to follow-up. During the first week, patients received 2.5 mg of oxybutynin once a day in the evening. From the 8th to the 42nd day, they received 2.5 mg twice a day, and from the 43rd day to the end of the 12th week, they received 5 mg twice a day. All of the patients underwent 2 evaluations: before and after (12 weeks) the oxybutynin treatment, using a clinical questionnaire; and a clinical protocol for quality of life (QOL).

Eligibility criteria: Inclusion Criteria:

* Adult patients with hyperhidrosis

Exclusion Criteria:

* Glaucoma and pregnancy

Primary outcomes:
measure: Improvement of Quality of life in patients with hyperhidrosis with the use of oxybutynin
timeFrame: 6 weeks
Secondary outcomes:
measure: The use of oxybutynin diminishes hyperhidrosis
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Hospital das Clinicas da FMUSP
Study officials:
affiliation: University of Sao Paulo
name: WOLOSKER NELSON, Md, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05824312: HRQOL in Locally Advanced Thyroid Carcinoma
Official title: Health-related Quality of Life of Patients With Locally Advanced Thyroid Cancer Receiving Targeted Therapy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Thyroid Cancer
Tyrosine Kinase Inhibitor
Health Related Quality of Life
Keywords: HRQOL
thyroid cancer
targeted therapy
Tyrosine kinase inhibitor
Lead sponsor: Fujian Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2023-04-21
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: locally advanced thyroid cancer

Brief summary: The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).

Detailed description: Surgical resection is the cornerstone of treatment for thyroid cancer. However, some patients present with locally advanced disease at the time of diagnosis, and they are not eligible for radical resection. Another patients still had the risk of recurrence after surgery, endocrine therapy and iodine-131 treatment. Tyrosine kinase inhibitors (TKI) have been proved to be effective in thyroid cancer patients. However, it was still unclear whether TKI drugs had influence on the HRQOL of LATC patients. The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).Participants enroll the study after informed consent, and quality of life will be assessed using quality of life questionnaires EORTC QLQ C30, and EORTC THY 47 before surgery, and 1,3,6 and 12 months after treatment.

Eligibility criteria: Inclusion Criteria:

* Patients age (18-70 year old)
* Diagnosis of locally advanced thyroid cancer
* Patient receiving TKI drugs.

Exclusion Criteria:

* pregnancy or breastfeeding women;
* history of other malignant diseases, unstable angina, myocardial infarction, cerebral infarction or cerebral hemorrhage within 6 months; (3) patients missing questionnaires greater than 3 times.

Primary outcomes:
measure: the global status of QLQ C30 questionnaire
timeFrame: 1 year
Secondary outcomes:
measure: Adversed events of TKI.
timeFrame: 1 year
measure: Change in fatigue score
timeFrame: 1 year
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: Road Fuma No.420
state: Fujian
Study officials:
affiliation: FujianMedical University Cancer Hospital
name: Hui Liu
role: STUDY_CHAIR
References:
Clinical trial NCT02206412: Role of High Mobility Group Box 1 as a Prognostic Biomarker in Patients Undergoing Off-pump Coronary Artery Bypass Graft
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Occlusive Disease
Keywords: high mobility group box 1
prognostic biomarker
off-pump coronary artery bypass graft
patients
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2014-08-01
Enrollment: 255
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients over age 20 who are undergoing off-pump coronary artery bypass graft

Brief summary: High mobility group 1 (HMGB1) protein is both a nuclear factor and a secreted protein, and has recently been identified as a cytokine mediator of systemic inflammation. HMGB1 is released by inflammatory cells actively, or increased during cell death passively and mediates inflammatory response. It has been reported to have association with the prognosis after acute coronary syndrome, ischemia-reperfusion injury of myocardium, atherosclerosis and heart failure. This study aimed to investigate the relationship of serum levels of HMGB1 and post operative prognosis of patients who had undergone off-pump coronary artery bypass graft.


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 20
2. Patients undergoing off-pump coronary artery bypass graft

Exclusion Criteria:

1. Age \< 20
2. Patients undergoing off-pump coronary artery bypass graft with other simultaneous surgery
3. Patients participating other study

Primary outcomes:
measure: Maximum value of HMGB1
timeFrame: Change from induction of anesthesia to 2hrs after transfer to intensive care unit
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology & Pain Medicine, Yonsei university college of medicine
Study officials:
References:
Clinical trial NCT01911312: Evaluation of Thermal-Aided Muscle Stimulation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Weakness
Atrophy
Lead sponsor: Niveus Medical, Inc.
Sponsor class: INDUSTRY
First posted: 2013-07-30
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: An investigation into the relative effectiveness of thermal-aided muscle stimulation vs. body temperature muscle stimulation for eliciting muscle contraction in the quadriceps


Eligibility criteria: Inclusion Criteria:

* Subject does not meet any exclusion criteria

Exclusion Criteria:

* Age \< 18 years
* Subject is pregnant
* Subject has an implanted pacemaker/defibrillator
* Subject diagnosed with epilepsy
* Subject has implanted metallic femoral rods
* Subject is chair- or bed-bound
* Subject has neuromuscular disease or abnormalities
* Subject BMI \> 45
* Evidence of disease or condition that, in the opinion of the investigator, may compromise the conduct of or results of the study

Primary outcomes:
measure: Muscle Contraction Force
timeFrame: At 30 s intervals for 20 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Mountain View
country: United States
facility: Melchor Pavilion
state: California
Study officials:
References:
Clinical trial NCT04118712: Pediatric Ovarian Tissue Banking - Operative Specimens From Females 0-18 Years of Age
Official title: Pediatric Ovarian Tissue Banking - Operative Specimens From Females 0-18 Years of Age
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Benign Cysts Ovarian
Cystectomy
Torsion
Malignant Cysts Ovarian
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Sponsor class: OTHER
First posted: 2019-10-08
Enrollment: 100
Sex: FEMALE
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient recruitment could occur in either the pediatric surgery outpatient clinic or during hospital admission depending on the underlying condition and urgency of the procedure.

Brief summary: A child is eligible to participate in this study because she is having surgery on her ovary. The investigators may obtain a sample of any discarded tissue from the surgery for an ovarian tissue library. This study is being conducted to understand how common ovarian conditions effect the number and quality of ovarian follicles and the reproductive potential of the ovary.

Detailed description: The investigators intend to enroll 100 girls and women in this study who are undergoing surgery involving the ovary. This may include patients with different conditions for comparison, such as ovarian cysts or masses and ovarian torsion. For each patient, the investigators will obtain the discarded tissue from the operating room after the affected ovarian tissue is resected. The tissue sample will only be taken for the tissue library from ovarian tissue that would otherwise be discarded.

No additional tissue will be collected other than that which is already removed as part of the ovarian procedure. No additional surgery or other procedures will be performed for the purposes of this study. The tissue will be assigned a study ID number and the age, gender and diagnosis of the child will be entered on the tissue library log and maintained for the duration of the study.

Eligibility criteria: Inclusion Criteria:

* Pre and Post Pubertal females
* Ages 0-18 years old
* Undergoing scheduled or emergent operative procedures involving the ovary

  1. oophorectomy (torsion, benign mass/cyst, malignant mass/cyst)
  2. ovarian cystectomy

Exclusion Criteria:

* Pregnant females

Primary outcomes:
measure: Ovarian Tissue Banking
timeFrame: October 2016- December 2030
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Ann & Robert H Lurie Childrens Hospital
state: Illinois
Study officials:
affiliation: Ann & Robert H Lurie Children's Hospital of Chicago
name: Erin Rowell, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04471012: The Transtheoretical Model For Polycystic Ovary Syndrome
Official title: Impact of The Individual Counseling Program Using The Transtheoretical Model For Polycystic Ovary Syndrome Management Among University Students
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Polycystic Ovary Syndrome
Keywords: transtheoretical model
individual counselling
university students
Lead sponsor: Afyonkarahisar Health Sciences University
Sponsor class: OTHER
First posted: 2020-07-14
Enrollment: 67
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 24
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The main objective of this study was to investigate the impact of individual counseling programs which has been designed from the Transtheoretical Model (TM) suggesting a healthy diet and physical activity for the students diagnosed with PCOS in the management of their syndrome. The data for the analysis was drawn from a sample of 854 students at first and a totally of 67 students were administered the scales. The control (N=33) and experimental groups (N=34) were formed based on a simple randomization technique.


Eligibility criteria: Inclusion Criteria:

* voluntary participation
* absence of sexual activity
* belonging to the age group of 19-24
* absence of chronic diseases
* absence of any physical disability and a lack of mental disorders.

Exclusion Criteria:

* being on medicine
* scores of above 18.5 and below 30 on the Body Mass Index (BMI)

Primary outcomes:
measure: Anthropometric Measurement
timeFrame: 1st month
measure: Anthropometric Measurement Change
timeFrame: 3rd month
measure: Anthropometric Measurement Change
timeFrame: 5th month
Secondary outcomes:
Other outcomes:
Locations:
city: Afyonkarahisar
country: Turkey
facility: Afyonkarahisar Health Science University
Study officials:
affiliation: Afyonkarahisar Health Science University
name: Dilek OCALAN, PhD
role: PRINCIPAL_INVESTIGATOR
References: